Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer's disease.

Authors :: Snider BJ
Holtzman DM
Source :: Neuron [Neuron] 2021 Oct 20; Vol. 109 (20), pp. 3199-3202. Date of Electronic Publication: 2021 Aug 24.
Publication Year :: 2021
Abstract: The COVID-19 pandemic has had a profound impact on neuroscientists, including those involved in translational research. In this NeuroView, we discuss the positive and negative effects of the pandemic on preclinical research and clinical studies in humans.<br />Competing Interests: Declaration of interests D.M.H. is an inventor on a patent licensed by Washington University to C2N Diagnostics and subsequently to AbbVie on the therapeutic use of anti-tau antibodies. D.M.H. is an inventor on a patent licensed by Washington University to Eli Lilly on a humanized anti-amyloid-β antibody. D.M.H. co-founded and is on the scientific advisory board to C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and Cajal Neurosciences and consults for Genentech, Takeda, and Eli Lilly. The lab of D.M.H. receives research funding to Washington University from C2N Diagnostics, Novartis, and NextCure. B.J.S. is on the Biogen advisory board.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)

Subjects :: Alzheimer Disease therapy
Biomedical Research trends
COVID-19 prevention & control
Humans
Neurodegenerative Diseases epidemiology
Neurodegenerative Diseases therapy
Neurology trends
Alzheimer Disease epidemiology
Biomedical Research methods
COVID-19 epidemiology
Clinical Trials as Topic methods
Neurology methods

Full Text Access

Tools